Can a standardized Watch-and-Wait plan reduce prostate cancer overtreatment?

NCT ID NCT02914873

Ongoing Disease control Sponsor: Uppsala University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a standardized active surveillance protocol to usual care for men with low-risk prostate cancer. The goal is to see if a clear set of rules for when to start treatment can reduce unnecessary treatments and side effects without raising the risk of cancer spread. About 2008 men will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: active surveillance (monitoring with delayed treatment if needed)
What this could lead to: If successful, this could help many men with low-risk prostate cancer avoid unnecessary treatments and side effects while staying safe.
What could go wrong: This is a large but early-stage comparison study; the standardized protocol may not prove better than current practice, and some men might still face disease progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Akademiska University Hospital

Uppsala, Sweden
Bedford Hospital

Bedford, United Kingdom
Croydon University Hospital

Croydon, United Kingdom
Epsom and St Helier Hospital

London, United Kingdom
Guy's Hospital

London, United Kingdom
Helsinki University Hospital

Helsinki, Finland
Hospital of Vestfold

Tønsberg, Norway
Linköping University Hospital

Linköping, Sweden
Odense University Hospital

Odense, Denmark
Oslo University Hospital

Oslo, Norway
Queen Elisabeth Hospital

London, United Kingdom
Rigshospitalet

Copenhagen, Denmark
Royal Marsden Hospital

London, United Kingdom
Sahlgrenska University Hospital

Gothenburg, Sweden
Seinäjoki Central Hospital

Tampere, Finland
St Olavs University Hospital

Trondheim, Norway
Sunderby Regional Hospital

Luleå, Sweden
Sundsvall Regional Hospital

Sundsvall, Sweden
Umeå University Hospital

Umeå, Sweden
University Hospital of North Norway

Tromsø, Norway
Växjö Hospital

Vaxjo, Sweden
Ålesund Regional Hospital

Ålesund, Norway
Örebro University Hospital

Örebro, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.